Catalyst Investments

Catalyst Fund is a private equity firm established in 1999, with offices in Israel and Hong Kong. Based in Tel Aviv, the firm focuses on investing in late-stage Israeli and Israeli-related companies, particularly in the technology sector. With over $200 million under management, Catalyst Fund targets companies that are either in distressed situations or at the pre-IPO and expansion stages. The firm's investment team is dedicated to assisting portfolio companies in achieving their objectives by leveraging a broad network across Europe and Israel. Catalyst Fund has a strong track record, with many of its portfolio companies successfully exiting through initial public offerings or mergers and acquisitions.

9 past transactions

Raziel Health

Series C in 2019
Raziel Health is focused on developing innovative treatments for obesity and fat disorders, particularly through its injectable drug RZL-012. This novel synthetic small molecule is designed to be injected directly into fat tissue, where it induces fat cell death, leading to a reduction in fat at the injection site. The company, founded in 2012 and based in Rehovot, Israel, aims to provide accessible and cost-effective healthcare solutions that enhance patient experience and promote timely clinical interventions. By integrating user-friendly technologies and leveraging data analytics, Raziel Health supports wellness and disease management, ensuring that individual patient goals are met effectively.

Arbe

Series B in 2019
Arbe Robotics Ltd develops 4D Imaging Radar technology that enable driver-assist systems while opening the way for completely autonomous driving. It is a research and development business specializing on chips for advanced radar systems, which are primarily intended for usage as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as non-automotive applications.

Eloxx

Series C in 2017
Eloxx Pharmaceuticals based in Israel is a Pontifax portfolio company established in 2013 by Dr. Silvia Noiman, that serves as its Executive Chairman and Dr. Shmuel Tuvia. The company, is a biopharmaceutical company focused on discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsense mutations including: Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome and many others. Eloxx Pharmaceuticals approach and knowhow allows moving rapidly from target drugs discovery program to clinical drug candidates. Building a robust pipeline of molecules designed for an array of nonsense genetic diseases. Translation of mRNA to a protein is the event where the cellular machinery, i.e. ribosome, ultimately dictates the quantity and timing for each protein to be produced. Thus, molecules that induce ribosomal readthrough overcome the nonsense mutations and allow production of a full-length functional protein. These molecules hold great therapeutic potential for the treatment of many genetic diseases.

XJet

Venture Round in 2016
Established in Rehovot, the hub of the Israeli “Silicon Valley”, XJet boasts 50 multidisciplinary R&D specialists and has filed more than 50 registered and pending patents. Originally it developed a solution for the solar industry, and expanded into the additive manufacturing world in 2013. With a decade’s-worth of research behind it, XJet pioneered NanoParticle Jetting™ technology to transform the metal additive manufacturing industry. Bringing a new level of quality to metal manufacturing, XJet’s NanoParticle Jetting™ technology uses solid metal nanoparticles suspended in liquid “ink” in sealed cartridges. An ultra-fine layer of liquid droplets containing stochastic metal and support nanoparticles is deposited onto the system build-tray. This produces metal parts with the same ease and versatility of inkjet printing without compromising throughput.

Dibs Technology

Seed Round in 2016
Dibs gives you quick and easy access to real-time pricing for the boutique fitness classes you want. Dibs is a platform (web and app) that makes it easy for the fitness industry to maximize revenues by pricing group classes (and eventually all visits) according to real-time demand instead of charging one price across the board, similar to the pricing that airlines use.

Aerodeon

Venture Round in 2003
Operates as an advertising agency that connects brands to consumers over mobile networks.

Orex Computed Radiography Ltd

Venture Round in 2001
Orex Computed Radiography manufactures computerized radiography solutions. The company’s products includes Kodak Point-of-Care CR120, CR140, and CR260 that enables medical practitioners to acquire patient digital x-ray images from around the world. KODAK Point-of-Care CR-ITX 560 is a solution system that brings digital x-ray imaging directly to the patient. KODAK CR 7400 Digital Radiography is a system that delivers intraoral and extra oral images digitally. Orex Computed Radiography is an Israel-based company that was founded in 1996. The company was acquired by Kodak on January 19, 2005.

Scopus Video Networks

Series A in 2001
Scopus Video Networks develop, market and support digital video networking products, including intelligent video gateways, encoders, decoders and network management products. Their customers include satellite, cable and telecom service providers and terrestrial broadcasters, collectively referred to as network operators.

TellSoft Technologies

Venture Round in 1999
TellSoft Technologies is a software company that offers a range of media services to its clients. It was founded in 1989 and was acquired by REBAR in 2001.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.